Plasma cyclophosphamide assay by selective ion monitoring.

  title={Plasma cyclophosphamide assay by selective ion monitoring.},
  author={C. Lartigue-Mattei and Jean Louis Chabard and Chlo{\'e} Touzet and H. Bargnoux and J. Petit and J. A. Berger},
  journal={Journal of chromatography},
  volume={310 2},
Efforts to Ensure Safety of Hospital Pharmacy Personnel Occupationally Exposed to Antineoplastic Drugs during a Preparation Task
Pharmacists on a rotating schedule who work less than 6 hours per week on preparatory tasks were not unduly exposed to antineoplastics, and the SCE levels were within the normal limits for all the subjects.
Cyclophosphamide and related anticancer drugs.
  • F. BaumannR. Preiss
  • Chemistry
    Journal of chromatography. B, Biomedical sciences and applications
  • 2001
Determination of iphosphamide and seven metabolites in blood plasma, as stable trifluoroacetyl derivatives, by electron capture chemical ionization GC‐MS
A method is described for the determination of the antitumor agent iphosphamide and seven of its metabolites in the plasma of cancer patients by multiple ion monitoring (MIM) GC-MS, mainly using the
The determination of cyclophosphamide and its metabolites in blood plasma as stable trifluoroacetyl derivatives by electron capture chemical ionization gas chromatography/mass spectrometry.
A method is described for the determination of the antitumour drug cyclophosphamide and six stable metabolites in plasma of cancer patients as methyl and/or trifluoroacetyl derivatives by single ion monitoring gas chromatography/mass spectrometry, mostly in the electron capture chemical ionization mode.
Chromatographic analysis of anticancer drugs.
Monitoring the behaviour of 4-ketocyclophosphamide versus cyclophosphamide during capillary gas chromatography by mass spectrometry.
It appeared that in situ cyclization of 4-keto CPA was negligible (less than 5%), probably owing to extra stabilization of the CPA metabolite by keto-enol tautomerism as has been demonstrated by NMR.
The autoderivatization of 4-ketocyclophosphamide during capillary gas chromatography
The selectivity of a capillary gas chromatographic assay for the anti-neoplastic and immunosuppressive agent cyclophosphamide (CPA) towards one of its naturally occurring metabolites, i.e.
Urinary cyclophosphamide assay as a method for biological monitoring of occupational exposure to cyclophosphamide
Urine of twenty hospital workers was monitored for the excretion of the cytostatic drug cyclophosphamide using GC-MSD and a clear relationship between cycloph phosphamide handling and the detectability of excretion existed.


Pharmacokinetics of cyclophosphamide in man
The pharmacokinetics of cyclophosphamide were investigated in cancer patients in a two-compartment open model and the calculated fraction of the dose of drug which was metabolized averaged 88%.
Phenobarbital effects on cyclophosphamide pharmacokinetics in man.
Summary Plasma concentrations and urinary excretion rates of cyclophosphamide and its total metabolites were measured after i.v. administration of 500- to 1000-mg doses of radiolabeled
Quantitative GLC determination of cyclophosphamide and isophosphamide in biological specimens.
A method for measuring the antitumor agent cyclophosphamide was developed and applied to the determination of the drug in biological specimens, and linearity was found up to microgram amounts of substance, without any interference of endogenous substrates.
The quantitation of cyclophosphamide in human blood and urine by mass spectrometry-stable isotope dilution.
Quantitation by gas chromatography-chemical ionization mass spectrometry of cyclophosphamide, phosphoramide mustard, and nornitrogen mustard in the plasma and urine of patients receiving cyclophosphamide therapy.
Unambiguous and sensitive methods based on gas chromatography-chemical ionization mass spectrometry have been developed to quantitate cyclophosphamide and two alkylating and cytotoxic metabolites,